GDC-0570
GDC-0570 is a novel, potent, selective, orally active pan-PIM inhibitor. GDC-0570 demonstrates synergistic antitumor efficacy when combined with Sotorasib (HY-114277) in acquired KRASis-resistant NSCLC.
For research use only. We do not sell to patients.
- CAS No.: 1586041-58-8
- Formula: C20H20F3N5O2S
- Molecular Weight:451.47
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 1586041-58-8
-
Molecular Weight 451.47
-
Formula C20H20F3N5O2S
-
SMILES
O=C(C1=CSC(C2=C(C=CC=C2F)F)=N1)NC3=C([C@@H]4CC[C@H]([C@@H](CO4)F)N)N(N=C3)C
-
Synonyms
NB004
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Patient-Derived Xenograft (PDX)
Patient-derived xenograft (PDX) models are generated by engrafting primary human tumor tissue directly into immunodeficient mice, allowing in vivo propagation of patient tumor biology without initial in vitro adaptation. These models are used to preserve key histopathological and molecular characteristics of the original tumor and enable assessment of tumor growth dynamics and therapeutic response in a living organism. The biological readout is tumor engraftment and subsequent growth in the murine host, which reflects the ability of human tumor cells to survive, vascularize, and expand in an immunocompromised microenvironment.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)